Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy

Immune effector cell-associated enterocolitis (IEC-EC) is a delayed toxicity of ciltacabtagene autoleucel. The US Multiple Myeloma Immunotherapy Consortium retrospectively adjudicated 54 suspected cases from 8 institutions: 41 were IEC-EC (31 confirmed by anti-camelid variable heavy-chain immunohistochemistry, 10 probable). Through September 2025, cumulative incidence was 3.0% (39 of 1,308 ciltacabtagene autoleucel recipients; 95% CI 2.1–4.1%); 12-month competing-risk incidence was 3.0% (95% CI 2.1–4.1%). Median symptom onset was 75 days after infusion. Grade ≥3 diarrhea occurred in 85% (34 of 40 with diarrhea); 73% (30 of 41) required parenteral nutrition. Despite normal upper endoscopy in 41% (9 of 22), duodenal biopsies showed villous blunting, apoptotic bodies and a dense cytotoxic T cell infiltrate, CD4 + in 61% (19 of 31), CD8 + in 26% (8 of 31) and mixed in 13% (4 of 31). A dominant T cell clone was detected in 76% (13 of 17 tested). Delayed neurotoxicity co-occurred in 41% (17 of 41). At last follow-up, 32% (13 of 41) resolved, 27% (11 of 41) had ongoing symptoms and 41% (17 of 41) died with active IEC-EC. Combined biologic and T cell-directed therapy yielded the highest resolution (55%, 6 of 11) in small subgroups. IEC-EC is potentially fatal and requires systematic evaluation and early directed therapy.

Authors

Institutions

Publication Details

Journal
Nature Medicine
Published
2026-11-19
DOI
https://doi.org/10.1038/s41591-026-04783-y
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy

Rebecca M. Gonzalez, Ajai Chari, Francisco Vega, Sharlene Dong et al.
Nature Medicine
CAR-T cell therapy research
article

Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy

Rebecca M. Gonzalez, Ajai Chari, Francisco Vega, Sharlene Dong, Mark P. Hamilton, Jeffrey Lee Wolf, Ghulam Rehman Mohyuddin, Yi Lin, Surbhi Sidana, Frederick Lundry Locke, Rahul Kumar Banerjee, Hitomi Hosoya, Alaa Ali, Andrew Jay Portuguese, Max N. Brondfield, Alexandria M. Jensen, Lekha Mikkilineni, Nadine H. Abdallah, Zongming Eric Chen, Omar Alexis Castaneda Puglianini, Doris K. Hansen, Douglas Weston Sborov, Amandeep Godara, Sebastian Fernandez‐Pol, Binod Dhakal, David Yoonsuk Oh, Kenneth J C Lim, Krina K. Patel, Dana J. Balitzer, NAVREET M. CHOWLA, Michael G. Kattah, Anna Shestakova, Metin Özdemirli, Christopher James Ferreri, David Bernard Miklos, Louis S. Williams, Thomas G Martin, Christopher Bowman, Jinming Song, Anupama D. Kumar, Gliceida M. Galarza-Fortuna
article en

Abstract

Immune effector cell-associated enterocolitis (IEC-EC) is a delayed toxicity of ciltacabtagene autoleucel. The US Multiple Myeloma Immunotherapy Consortium retrospectively adjudicated 54 suspected cases from 8 institutions: 41 were IEC-EC (31 confirmed by anti-camelid variable heavy-chain immunohistochemistry, 10 probable). Through September 2025, cumulative incidence was 3.0% (39 of 1,308 ciltacabtagene autoleucel recipients; 95% CI 2.1–4.1%); 12-month competing-risk incidence was 3.0% (95% CI 2.1–4.1%). Median symptom onset was 75 days after infusion. Grade ≥3 diarrhea occurred in 85% (34 of 40 with diarrhea); 73% (30 of 41) required parenteral nutrition. Despite normal upper endoscopy in 41% (9 of 22), duodenal biopsies showed villous blunting, apoptotic bodies and a dense cytotoxic T cell infiltrate, CD4 + in 61% (19 of 31), CD8 + in 26% (8 of 31) and mixed in 13% (4 of 31). A dominant T cell clone was detected in 76% (13 of 17 tested). Delayed neurotoxicity co-occurred in 41% (17 of 41). At last follow-up, 32% (13 of 41) resolved, 27% (11 of 41) had ongoing symptoms and 41% (17 of 41) died with active IEC-EC. Combined biologic and T cell-directed therapy yielded the highest resolution (55%, 6 of 11) in small subgroups. IEC-EC is potentially fatal and requires systematic evaluation and early directed therapy.

Nature Medicine
Cedars-Sinai Medical Center (US), Cleveland Clinic (US), Mayo Clinic (US), The University of Texas MD Anderson Cancer Center (US), University of California, San Francisco (US), Georgetown University (US), Medical College of Wisconsin (US), University of Utah (US), Georgetown University Medical Center (US), Huntsman Cancer Institute (US), Moffitt Cancer Center (US), Fred Hutch Cancer Center (US), Levine Cancer Institute (US), Stanford Medicine (US), Alfred Health (AU), Georgetown Lombardi Comprehensive Cancer Center (US), Wake Forest University (US), Monash University (AU), ARUP Laboratories (United States) (US), Stanford University (US)
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon